Sex Hormone Binding Globulin, Testosterone and Glycemic Control in Patients With Type 2 Diabetes

N

Nanjing Medical University

Status

Completed

Conditions

Type2 Diabetes

Study type

Observational

Funder types

Other

Identifiers

NCT03519529
ENDO20180426-01

Details and patient eligibility

About

Sex hormone-binding globulin(SHBG) is a surrogate marker of insulin resistance. This study aims at the characteristic and clinical significance of SHBG and testosterone in patients with type 2 diabetes(T2D).

Full description

The investigators recorded clinical factors, biochemical criterion such as serum levels of glucose and lipids, HbA1c, SHBG, testosterone, insulin, EPO, C-peptide, glucagon, microalbuminuria, glycemic variation via CGM, carotid plaque, ECG and ultrasonic cardiogram in patients with T2D who visited in the Department of Endocrinology at the Nanjing First Hospital from January 2015 to Aprol 2018. The relationship between levels of SHBG, testosterone and glycemic variation/diabetic complications are analysed.

Enrollment

250 patients

Sex

Male

Volunteers

No Healthy Volunteers

Inclusion criteria

● Patients with T2D and the diagnostic criteria of T2D is according to the World Health Organization in 1999.

Exclusion criteria

  • Patients use systemic steroidal anti-inflammatory drugs.
  • Patients with an acute infection.
  • Patients with acute complication of diabetes.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems